title: Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
authors.affiliation: Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany. stephan.glund@boehringer-ingelheim.com.
authors.forename: Stephan
authors.identifier: 0000-0003-4582-3679
authors.initials: S
authors.lastname: Glund
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Reilly
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
authors.forename: Joanne
authors.initials: J
authors.lastname: van Ryn
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
authors.forename: Joachim
authors.initials: J
authors.lastname: Stangier
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics*; D000991:Antithrombins; D000069604:Dabigatran; D004311:Double-Blind Method; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran